AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33657038 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized CRC screening approaches
Number of subjects: 0
Study 33657038 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive screening tests to diagnostic colonoscopy
Number of subjects: 0
Study 33657038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective, highly accurate, noninvasive modalities
Number of subjects: 0
Study 33657112 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIKV non-infected women
Number of subjects: 731
Study 33657112 — intervention group
Group type: COMPARATOR
Intervention: ZIKV-exposed infants
Number of subjects: 731
Study 33657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-stored RBCs
Number of subjects: 0
Study 33657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion through human spleen
Number of subjects: 0
Study 33657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of long-stored RBCs
Number of subjects: 0
Study 33657208 — intervention group
Group type: COMPARATOR
Intervention: Macrophage-depleted mice
Number of subjects: 0
Study 33657217 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement learning (RL) algorithm for increasing physical activity
Number of subjects: 0
Study 33657398 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 50
Study 33657398 — intervention group
Group type: COMPARATOR
Intervention: CMR
Number of subjects: 50
Study 33657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of AxiSanté 5-Infansoft software for electronic medical records by pediatricians trained in infectious diseases.
Number of subjects: 57806
Study 33657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test for tonsillopharyngitis.
Number of subjects: 57806
Study 33657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment following French guidelines, specifically amoxicillin.
Number of subjects: 57806
Study 33657782 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) (22 gauge)
Number of subjects: 48
Study 33657782 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (EUS-FNA) (25 gauge)
Number of subjects: 48
Study 33657782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EUS-FNB and EUS-FNA
Number of subjects: 48
Study 33657786 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab + bortezomib/thalidomide/dexamethasone
Number of subjects: 0
Study 33657786 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33657839 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-Led Group Lifestyle Balance (PGLB) intervention
Number of subjects: 63
Study 33657843 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered healthy lifestyle intervention
Number of subjects: 0
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotics
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antithrombotics and statins
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation for atrial fibrillation
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypertension
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled dyslipidemia
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diabetes
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled diabetes
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled dyslipidemia
Number of subjects: 404
Study 33657859 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased use of statins
Number of subjects: 404
Study 33657991 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33658034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation support program (in-home lactation consultant visits, breast pumps)
Number of subjects: 199
Study 33658034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation support program
Number of subjects: 199
Study 33658034 — intervention group
Group type: COMPARATOR
Intervention: Maternal sociodemographics and food insecurity
Number of subjects: 199
Study 33658052 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) 0.10 mg/kg, 0.15 mg/kg, and 0.20 mg/kg IV infusions
Number of subjects: 11
Study 33658052 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 11
Study 33658056 — intervention group
Group type: EXPERIMENTAL
Intervention: In-scanner exercise stress cardiovascular magnetic resonance (ExCMR)
Number of subjects: 60
Study 33658056 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric approach using ExCMR
Number of subjects: 60
Study 33658056 — intervention group
Group type: COMPARATOR
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 60
Study 33658080 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-CAN®
Number of subjects: 19
Study 33658305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 33658610 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors for measuring total sleep opportunity (TSO) and total sleep time (TST)
Number of subjects: 32
Study 33658610 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors for measuring total scratching duration
Number of subjects: 32
Study 33658752 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification procedures
Number of subjects: 200
Study 33658841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/day)
Number of subjects: 334
Study 33658841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 33658915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) training for 12 weeks
Number of subjects: 38
Study 33658915 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline integrity of three target white matter tract groups
Number of subjects: 38
Study 33658980 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose challenge during OGTT
Number of subjects: 24
Study 33658980 — intervention group
Group type: COMPARATOR
Intervention: Control group (no family history of diabetes)
Number of subjects: 24
Study 33658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically modified immune cells
Number of subjects: 0
Study 33658994 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33659204 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg once daily
Number of subjects: 31
Study 33659204 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 425 mg once daily
Number of subjects: 31
Study 33659204 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib and etoposide
Number of subjects: 31
Study 33659227 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33659261 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 0
Study 33659261 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided therapy
Number of subjects: 0
Study 33659267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 33660142 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 33660142 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodality therapy
Number of subjects: 0
Study 33660142 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33660194 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3023414 200 mg BID
Number of subjects: 42
Study 33660197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 3437
Study 33660197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h Postprandial Blood Glucose (2hPG)
Number of subjects: 3437
Study 33660197 — intervention group
Group type: COMPARATOR
Intervention: Glycated Hemoglobin (HbA1c)
Number of subjects: 3437
Study 33660198 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg/flexibly dosed
Number of subjects: 2836
Study 33660198 — intervention group
Group type: COMPARATOR
Intervention: Comparator (placebo, sitagliptin 100 mg, or liraglutide 1.8 mg)
Number of subjects: 2836
Study 33660230 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban Prescriber Guide
Number of subjects: 510
Study 33660230 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban Patient Alert Card
Number of subjects: 510
Study 33660230 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall knowledge of bleeding risk among HCPs and patients
Number of subjects: 510
Study 33660625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use (specific cannabinoids not detailed)
Number of subjects: 0
Study 33660625 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33660690 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-WBC-SPECT/CT with conventional visual assessment
Number of subjects: 68
Study 33660690 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-WBC-SPECT/CT with semi-quantitative scoring system (CSI)
Number of subjects: 68
Study 33660691 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose-PET (18F-FDG-PET) scanning
Number of subjects: 64
Study 33661054 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33661120 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary synbiotic medical food
Number of subjects: 6
Study 33661120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 33661130 — intervention group
Group type: EXPERIMENTAL
Intervention: Manage My Pain app (MMP) used alongside standard care
Number of subjects: 246
Study 33661130 — intervention group
Group type: COMPARATOR
Intervention: Data entered on paper-based questionnaires (nonapp group)
Number of subjects: 246
Study 33661190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib, 840 mg PO QD
Number of subjects: 18
Study 33661190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 18
Study 33661274 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of circulating cell-free mitochondrial DNA (cf-mtDNA) in patients with SCD
Number of subjects: 0
Study 33661274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA in patient samples
Number of subjects: 0
Study 33661274 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient plasma containing high levels of cf-mtDNA
Number of subjects: 0
Study 33661274 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of TANK-binding kinase 1
Number of subjects: 0
Study 33661274 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating SCD red blood cells
Number of subjects: 0
Study 33661274 — intervention group
Group type: EXPERIMENTAL
Intervention: cf-mtDNA
Number of subjects: 0
Study 33661297 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance direct thrombus imaging (MRDTI)
Number of subjects: 10
Study 33661297 — intervention group
Group type: COMPARATOR
Intervention: Compression ultrasonography (CUS) alone
Number of subjects: 10
Study 33661297 — intervention group
Group type: EXPERIMENTAL
Intervention: CUS followed by MRDTI in case of inconclusive CUS
Number of subjects: 10
Study 33661297 — intervention group
Group type: COMPARATOR
Intervention: Strategies without MRDTI
Number of subjects: 10
Study 33661301 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (paclitaxel + carboplatin) plus nivolumab for 3 cycles followed by adjuvant nivolumab for 1 year
Number of subjects: 46
Study 33661521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 5136
Study 33661539 — intervention group
Group type: EXPERIMENTAL
Intervention: Antistaphylococcal cephalosporins
Number of subjects: 8073
Study 33661539 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum penicillins plus betalactamase inhibitors
Number of subjects: 8073
Study 33661539 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics
Number of subjects: 8073
Study 33661539 — intervention group
Group type: COMPARATOR
Intervention: Lavage
Number of subjects: 8073
Study 33662164 — intervention group
Group type: EXPERIMENTAL
Intervention: AIPS-E
Number of subjects: 292
Study 33662164 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-E
Number of subjects: 292
Study 33662447 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratified treatments based on disease biomarkers
Number of subjects: 350
Study 33662447 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation sequencing on bulk tumors
Number of subjects: 350
Study 33662447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell sequencing approaches
Number of subjects: 350
Study 33662597 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured by accelerometer: steps, time in any/moderate-to-vigorous/vigorous physical activity, intensity and sedentary time)
Number of subjects: 320
Study 33662597 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate recovery (HRR) and chronotropic response (CR) measured during a 6-min walk test (6MWT)
Number of subjects: 320
Study 33662654 — intervention group
Group type: EXPERIMENTAL
Intervention: Containment and mitigation measures (lockdown)
Number of subjects: 239
Study 33662654 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk and protective factors
Number of subjects: 239
Study 33662654 — intervention group
Group type: COMPARATOR
Intervention: Living conditions
Number of subjects: 239
Study 33663038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain extent
Number of subjects: 190
Study 33663084 — intervention group
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (ATG)
Number of subjects: 72
Study 33663084 — intervention group
Group type: COMPARATOR
Intervention: no ATG
Number of subjects: 72
Study 33663395 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for ambulance telecommunicators (20-min theory-based educational video)
Number of subjects: 0
Study 33663430 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust group
Number of subjects: 625
Study 33663430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail group
Number of subjects: 625
Study 33663430 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail group
Number of subjects: 625
Study 33663430 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 625
Study 33663527 — intervention group
Group type: EXPERIMENTAL
Intervention: PedsQL™ 4.0 generic health-related quality of life questionnaire
Number of subjects: 123
Study 33663560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus veliparib
Number of subjects: 20
Study 33663560 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 33663620 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSP implementation strategy including provider training, expert facilitation, and a five-step quality improvement process.
Number of subjects: 0
Study 33663745 — intervention group
Group type: EXPERIMENTAL
Intervention: European Society of Cardiology 0/1-h Algorithms
Number of subjects: 0
Study 33663941 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib at 240 mg daily in 28-day cycles
Number of subjects: 25
Study 33664072 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Motion-App for remote General Movement Assessment (GMA)
Number of subjects: 86
Study 33664072 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-point body tracker software
Number of subjects: 86
Study 33664072 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions for filming
Number of subjects: 86
Study 33664128 — intervention group
Group type: EXPERIMENTAL
Intervention: hu3S193, 30 mg/m² intravenous infusions
Number of subjects: 29
Study 33664128 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 29
Study 33664279 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SARS-CoV-2 antibodies
Number of subjects: 12928
Study 33664689 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical frailty (mobility frailty) or robust
Number of subjects: 429
Study 33664689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible cognitive frailty (RCF) and non-mobility RCF
Number of subjects: 429
Study 33664689 — intervention group
Group type: COMPARATOR
Intervention: Cognitive decline (CF)
Number of subjects: 429
Study 33665371 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcription-PCR testing
Number of subjects: 605
Study 33665371 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology testing
Number of subjects: 605
Study 33665371 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a person with confirmed COVID-19
Number of subjects: 605
Study 33665468 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Resilience for Healthy Kids (Healthy Kids) program
Number of subjects: 0
Study 33665614 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief vigorous stair climbing
Number of subjects: 0
Study 33665614 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33665745 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 16
Study 33666177 — intervention group
Group type: EXPERIMENTAL
Intervention: PwO
Number of subjects: 1000
Study 33666177 — intervention group
Group type: EXPERIMENTAL
Intervention: HCPs
Number of subjects: 1000
Study 33666246 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 3051
Study 33666246 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3051
Study 33666272 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33666562 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMan system (mobile app connected to a wristband and cloud services)
Number of subjects: 56
Study 33666654 — intervention group
Group type: EXPERIMENTAL
Intervention: iTregs at 3.0 × 106/kg
Number of subjects: 14
Study 33666654 — intervention group
Group type: EXPERIMENTAL
Intervention: iTregs at 3.0 × 107/kg
Number of subjects: 14
Study 33666654 — intervention group
Group type: EXPERIMENTAL
Intervention: iTregs at 3.0 × 108/kg with CSA/MMF
Number of subjects: 14
Study 33666654 — intervention group
Group type: COMPARATOR
Intervention: iTregs at 3.0 × 108/kg with sirolimus/MMF
Number of subjects: 14
Study 33666880 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline physical performance (SPPB score)
Number of subjects: 1679
Study 33666880 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline physical performance (HGS)
Number of subjects: 1679
Study 33666880 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GDS score
Number of subjects: 1679
Study 33667180 — intervention group
Group type: EXPERIMENTAL
Intervention: > 0 to < 1 drinks/d
Number of subjects: 3852
Study 33667180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to < 2 drinks/d
Number of subjects: 3852
Study 33667180 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 2 drinks/d
Number of subjects: 3852
Study 33667180 — intervention group
Group type: COMPARATOR
Intervention: Nondrinkers
Number of subjects: 3852
Study 33667197 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 rejection
Number of subjects: 7
Study 33667197 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 rejection
Number of subjects: 7
Study 33667197 — intervention group
Group type: EXPERIMENTAL
Intervention: VCA rejection
Number of subjects: 7
Study 33667197 — intervention group
Group type: COMPARATOR
Intervention: Grade 1 rejection
Number of subjects: 7
Study 33667672 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel smoothing splines (MSS) for capturing nonlinearity in quantitative predictors
Number of subjects: 0
Study 33667672 — intervention group
Group type: EXPERIMENTAL
Intervention: MSS modeling approach
Number of subjects: 0
Study 33667672 — intervention group
Group type: EXPERIMENTAL
Intervention: 3dMSS program
Number of subjects: 0
Study 33667672 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal dataset of structural MRI scans
Number of subjects: 0
Study 33668011 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 6857
Study 33668011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild smokers
Number of subjects: 6857
Study 33668011 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate smokers
Number of subjects: 6857
Study 33668011 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 6857
Study 33668061 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 272
Study 33668061 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 272
Study 33668061 — intervention group
Group type: COMPARATOR
Intervention: SABR
Number of subjects: 272
Study 33668562 — intervention group
Group type: EXPERIMENTAL
Intervention: Run Daddy Run intervention (co-created lifestyle intervention with six interactive father-child sessions and an eHealth component, delivered over a 14-week period)
Number of subjects: 0
Study 33668562 — intervention group
Group type: EXPERIMENTAL
Intervention: Run Daddy Run intervention
Number of subjects: 0
Study 33669675 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Composition (BC) parameters measured by dual-energy X-ray absorptiometry
Number of subjects: 17
Study 33669675 — intervention group
Group type: EXPERIMENTAL
Intervention: Training volume and pattern assessed via an author-developed questionnaire
Number of subjects: 17
Study 33669675 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury status assessed via a modified questionnaire on overuse injuries
Number of subjects: 17
Study 33669715 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based rhythmic auditory stimulation (RAS) in combination with conventional physiotherapy
Number of subjects: 55
Study 33669715 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 55